OLEMA PHARMACEUTICALS, INC. Proceeds from Issuance of Private Placement
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Proceeds from Issuance of Private Placement of $243.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. proceeds from issuance of private placement for the quarter ending 2023-12-31 was -$24.00K.
- OLEMA PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2024 was $243.50M, a 87.69% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. proceeds from issuance of private placement for fiscal 2023 was $129.74M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|
| 2024-12-31 | $243.50M 10-K · filed 2026-03-16 | ||
| 2023-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $129.74M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $129.76M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |